Related Experiment Videos
Treatment of serious infections with intravenous ciprofloxacin
Abstract:
Thirty-four patients were treated with intravenous ciprofloxacin. Thirty infections occurring in 28 patients were assessable for the efficacy analysis. The drug dosage was 300 mg every 12 hours in 19 patients and 200 mg intravenously every 12 hours in nine patients. Twelve patients were also given ciprofloxacin orally after initial intravenous therapy. The mean duration of total therapy was 31 days. The overall clinical response rate was 87 percent, and the bacteriologic response rate was 70 percent. Favorable responses were observed in 10 of 12 patients with osteomyelitis/septic arthritis; seven of eight with soft tissue infection; four of four with pneumonitis; one of two with cystic fibrosis; and four of four with urinary tract infections. Resistance to ciprofloxacin developed in three Pseudomonas aeruginosa isolates. Toxicity was minor: phlebitis occurred in six patients, nausea in six, and rash in one. Intravenously administered ciprofloxacin or intravenous ciprofloxacin followed by oral ciprofloxacin is a safe and effective therapy for serious infections.
Insights
Intravenous ciprofloxacin effectively treated serious infections in patients, showing high clinical and bacteriologic response rates. This antibiotic therapy proved safe with minor side effects, making it a viable treatment option.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Serious infections require effective antimicrobial therapy.
- Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic with activity against various pathogens.
- Intravenous administration allows for rapid achievement of therapeutic drug concentrations.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous ciprofloxacin for treating serious infections.
- To determine clinical and bacteriologic response rates in patients receiving ciprofloxacin therapy.
- To assess the development of antimicrobial resistance and adverse events associated with ciprofloxacin treatment.
Main Methods:
- A cohort of 34 patients received intravenous ciprofloxacin.
- Efficacy was assessed in 30 infections across 28 patients.
- Dosages varied (300 mg or 200 mg every 12 hours), with some patients receiving oral ciprofloxacin post-intravenous therapy.
Main Results:
- An overall clinical response rate of 87% and a bacteriologic response rate of 70% were observed.
- Favorable responses were noted across various infection types, including osteomyelitis, soft tissue infections, pneumonitis, and urinary tract infections.
- Ciprofloxacin resistance developed in three Pseudomonas aeruginosa isolates; toxicity was minor, with phlebitis and nausea being the most common adverse events.
Conclusions:
- Intravenous ciprofloxacin, alone or followed by oral administration, is a safe and effective treatment for serious infections.
- The study demonstrates a high success rate in treating diverse infections, including challenging cases like osteomyelitis.
- Monitoring for resistance and potential adverse effects is important during ciprofloxacin therapy.